Skip to content
  • Home
  • Our research
  • Market
  • Press release
  • Reports
  • Plans
  • Partnering
  • About us
Menu
  • Home
  • Our research
  • Market
  • Press release
  • Reports
  • Plans
  • Partnering
  • About us

Reports

2021

Annual report 2021
Interim report Q3 2021
Half-year report 2021
Interim report Q1 2021

2020

Annual report 2020
Year-end report 2020
Interim report Q3 2020
Half-year report 2020
Interim report Q1 2020

2019

Annual report 2019
Year-end report 2019
Interim report Q3 2019
Half-year report 2019
Interim report Q1 2019

2018

Annual report 2018
Year-end report 2018
Interim report Q3 2018
Half-year report 2018
Interim report Q1 2018

2017

Annual report 2017
Year-end report 2017
Interim report Q3 2017
Half-year report 2017
Interim report Q1 2017

2016

Annual report 2016
Year-end report 2016
Interim report Q3 2016
Half-year report 2016
Interim report Q1 2016

2015

Annual report 2015
Year-end report 2015
Interim report Q3 2015
Half-year report 2015
Interim report Q1 2015

2014

Annual report 2014
Year-end report 2014
Interim report Q3 2014
Prospectus Follicum

2013

Annual report 2013

2012

Annual report 2012

2011

Annual report 2011

Contact us

Kristian Lykke Fick

Send e-mail
Twitter Linkedin Facebook Youtube
As part of Coegin Pharma AB’s hub & spoke “portfolio” business model, with clear benefits to investors, Coegin Pharma AB has established the Swedish portfolio company Follicum AB to further develop a highly promising novel and proprietary dermatological drug candidate FOL005. Follicum AB will primarily be managed and financed separately from Coegin Pharma AB.
© All Rights Reserved